Study: Antibody tests risky in predicting COVID-19 individual immunity


Antibody tests for SARS-CoV-2, the virus causes COVID-19, are useful for population-level assessments, but risky for predicting individual immunity, according to a new study published in Science Immunology on Tuesday. 

Serological testing for SARS-CoV-2 has enormous potential to contribute to COVID-19 response efforts. However, the required performance characteristics of antibody tests will critically depend on the use case (individual-level vs. population-level), according to the study.

The study was jointly conducted by researchers from University of Utah Health, Johns Hopkins Bloomberg School of Public Health, Harvard School of Public Health, University of California, San Francisco and Pennsylvania State University. 

They believe antibody testing – even with moderate sensitivity and specificity levels – could provide highly valuable information to address critical public health questions, such as when to relax stay-at-home orders or school closures. 

Read more: 

Immunity tests – a tool to know how widespread the coronavirus is

Knowledge is power: Countries test virus prevalence in the population

Immunity passports to ease lockdown might trigger discrimination

In theory, antibody tests can examine whether a person has ever been exposed to a certain virus over their lifespan. However, what SARS-CoV-2 antibody test results mean for protection and immunity are still poorly understood. 

As tools to issue "immune passports" that certify an individual's immunity, current serological tests are insufficient and even harmful, said the researchers. 

By contrast, as tools to ascertain population-level epidemiological trends, serological surveys could help officials estimate the risk of future waves of disease, measure the impact of interventions, and confirm the absence of transmission after the epidemic has subsided, as long as the tests' sensitivity and specificity are well-defined during data interpretation, according to the study. 

Population-level serological sampling could enable screening of multiple biomarkers of public health concern, extending the utility of such a framework beyond SARS-CoV-2 alone, said the researchers.

Source(s): Xinhua News Agency